Cardiovascular Pharmacogenomics: Does It Matter if You're Black or White?

Tanima De, C. Sehwan Park, Minoli Perera

Research output: Contribution to journalReview article

Abstract

Race and ancestry have long been associated with differential risk and outcomes to disease as well as responses to medications. These differences in drug response are multifactorial with some portion associated with genomic variation. The field of pharmacogenomics aims to predict drug response in patients prior to medication administration and to uncover the biological underpinnings of drug response. The field of human genetics has long recognized that genetic variation differs in frequency between ancestral populations, with some single nucleotide polymorphisms found solely in one population. Thus far, most pharmacogenomic studies have focused on individuals of European and East Asian ancestry, resulting in a substantial disparity in the clinical utility of genetic prediction for drug response in US minority populations. In this review, we discuss the genetic factors that underlie variability to drug response and known pharmacogenomic associations and how these differ between populations, with an emphasis on the current knowledge in cardiovascular pharmacogenomics.

Original languageEnglish (US)
Pages (from-to)577-603
Number of pages27
JournalAnnual Review of Pharmacology and Toxicology
Volume59
DOIs
StatePublished - Jan 6 2019

Fingerprint

Pharmacogenetics
Pharmaceutical Preparations
Population
Medical Genetics
Polymorphism
Single Nucleotide Polymorphism
Nucleotides
hydroquinone

Keywords

  • Cardiovascular
  • Genetic variation
  • Minority populations
  • Pharmacogenomics
  • Polymorphism

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

@article{aeccf61dfcf24ddcbb870a2518483fd2,
title = "Cardiovascular Pharmacogenomics: Does It Matter if You're Black or White?",
abstract = "Race and ancestry have long been associated with differential risk and outcomes to disease as well as responses to medications. These differences in drug response are multifactorial with some portion associated with genomic variation. The field of pharmacogenomics aims to predict drug response in patients prior to medication administration and to uncover the biological underpinnings of drug response. The field of human genetics has long recognized that genetic variation differs in frequency between ancestral populations, with some single nucleotide polymorphisms found solely in one population. Thus far, most pharmacogenomic studies have focused on individuals of European and East Asian ancestry, resulting in a substantial disparity in the clinical utility of genetic prediction for drug response in US minority populations. In this review, we discuss the genetic factors that underlie variability to drug response and known pharmacogenomic associations and how these differ between populations, with an emphasis on the current knowledge in cardiovascular pharmacogenomics.",
keywords = "Cardiovascular, Genetic variation, Minority populations, Pharmacogenomics, Polymorphism",
author = "Tanima De and {Sehwan Park}, C. and Minoli Perera",
year = "2019",
month = "1",
day = "6",
doi = "10.1146/annurev-pharmtox-010818-021154",
language = "English (US)",
volume = "59",
pages = "577--603",
journal = "Annual Review of Pharmacology and Toxicology",
issn = "0362-1642",
publisher = "Annual Reviews Inc.",

}

Cardiovascular Pharmacogenomics : Does It Matter if You're Black or White? / De, Tanima; Sehwan Park, C.; Perera, Minoli.

In: Annual Review of Pharmacology and Toxicology, Vol. 59, 06.01.2019, p. 577-603.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Cardiovascular Pharmacogenomics

T2 - Does It Matter if You're Black or White?

AU - De, Tanima

AU - Sehwan Park, C.

AU - Perera, Minoli

PY - 2019/1/6

Y1 - 2019/1/6

N2 - Race and ancestry have long been associated with differential risk and outcomes to disease as well as responses to medications. These differences in drug response are multifactorial with some portion associated with genomic variation. The field of pharmacogenomics aims to predict drug response in patients prior to medication administration and to uncover the biological underpinnings of drug response. The field of human genetics has long recognized that genetic variation differs in frequency between ancestral populations, with some single nucleotide polymorphisms found solely in one population. Thus far, most pharmacogenomic studies have focused on individuals of European and East Asian ancestry, resulting in a substantial disparity in the clinical utility of genetic prediction for drug response in US minority populations. In this review, we discuss the genetic factors that underlie variability to drug response and known pharmacogenomic associations and how these differ between populations, with an emphasis on the current knowledge in cardiovascular pharmacogenomics.

AB - Race and ancestry have long been associated with differential risk and outcomes to disease as well as responses to medications. These differences in drug response are multifactorial with some portion associated with genomic variation. The field of pharmacogenomics aims to predict drug response in patients prior to medication administration and to uncover the biological underpinnings of drug response. The field of human genetics has long recognized that genetic variation differs in frequency between ancestral populations, with some single nucleotide polymorphisms found solely in one population. Thus far, most pharmacogenomic studies have focused on individuals of European and East Asian ancestry, resulting in a substantial disparity in the clinical utility of genetic prediction for drug response in US minority populations. In this review, we discuss the genetic factors that underlie variability to drug response and known pharmacogenomic associations and how these differ between populations, with an emphasis on the current knowledge in cardiovascular pharmacogenomics.

KW - Cardiovascular

KW - Genetic variation

KW - Minority populations

KW - Pharmacogenomics

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=85059799069&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059799069&partnerID=8YFLogxK

U2 - 10.1146/annurev-pharmtox-010818-021154

DO - 10.1146/annurev-pharmtox-010818-021154

M3 - Review article

VL - 59

SP - 577

EP - 603

JO - Annual Review of Pharmacology and Toxicology

JF - Annual Review of Pharmacology and Toxicology

SN - 0362-1642

ER -